Neue Studie beurteilt den Einsatz von Masimo PVi zur Überwachung des Volumenstatus bei spontan atmenden Hämodialysepatienten
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Studie zur Nützlichkeit von Masimo O3 bei der Überwachung von IPS-Patienten mit septischem Schock und der Vorhersage der Sterblichkeit
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Rubius Therapeutics posts $42.3M loss in Q1
RUBIUS THERAPEUTICS reported a $42.3 million loss in the first quarter of 2021.
CAMBRIDGE, Mass. – Rubius Therapeutics Inc. reported a $42.3 million loss in the first quarter of 2021, or 51 cents per diluted share, the company said Monday.
The clinical-stage biopharmaceutical company posted a $48.5 million loss in the first quarter one year prior, or 60 cents per diluted share. The company owns and operates a manufacturing facility in North Smithfield.
In the first quarter of 2021, the company incurred $27.7 million in research and development costs, a decline from $36.2 million one year prior, and $13.2 million in general and administrative costs, an increase from $12.7 million one year prior.